Published April 12, 2018
Stimulating the immune system to work harder to attack cancer cells is referred as immunotherapy. From past 10 years, immunotherapy had played a major role in the treatment of cancer. Immunotherapy works better for treatment of some types of cancer. Different types cancers have different types of immunotherapies.
Asia Pacific Cancer Immunotherapy Market Segments Size & Growth:
Asia Pacific Cancer Immunotherapy Market is estimated to increase by an $XX billion by 2024 at a CAGR of XX%. Augmenting adoption of immunotherapy over other treatment options and increased development of bioinformatic tools enhancing drug development process are the key drivers accelerating to growth. Rising incidence of cancer and growth in adoption of advanced therapeutics are major drivers accelerating the overall market growth. High cost for medications hindering the market growth. Growth in clinical trials in against several types of therapies is one of the major important opportunities for the market. Increasing R&D in cancer immunotherapy is resulting in the introduction of advanced treatment options that are more effective and efficient.
Asia Pacific Cancer Immunotherapy Market Segments Share:
Based on production, cancer immunotherapy is further divided into checkpoint Inhibitors, monoclonal antibodies, cell therapies, vaccines, and immunomodulators. Monoclonal antibodies are class of antibodies produced by identical hybridoma cells. With the help of various advanced and powerful technologies which are being used in areas of biochemistry, biology, biotechnology, medical sciences, and immunology. These are sub-bodies are further divided into conjugated monoclonal antibodies, bispecific monoclonal antibodies, and naked monoclonal antibodies. Advancements in monoclonal antibodies include phase display, hybridoma technology, single B cell amplification and many advancements. Vaccines are further divided into tumor cell vaccines, Allogeneic tumor cell vaccines, DC vaccines, peptide-based cancer vaccines, genetic vaccines and some other.
Application segment includes colorectal cancer, melanoma, prostate cancer, lung cancer, head & neck cancer, multiple myeloma, breast cancer and others. Lung cancer is estimated to have the largest share during the forecasting period. The major driver includes increasing incidences of lung cancer these days. About 85% of deaths nowadays are happening due to smoking. In U.S more than one million people are diagnosed with cancer every year. Rising demand for advanced treatment options is also a major driver for the market growth.
Cancer immunotherapy by the end user is further divided into hospitals, clinics, and some others. Hospitals segment is projected to have the highest market size over 2018-2024. Increase in investments in the healthcare sector and numerous increase in usage of the immunotherapy drugs in different hospitals are accelerating the cancer immunotherapy market growth.
Based on geography, cancer immunotherapy is segmented into the Asia Pacific. Asia Pacific is estimated to be the fastest growing region with a moderate CAGR during the forecasting period. Increasing incidence of the disease and increasing patient population and new developments in immunotherapy are the major drivers for the accelerating the growth.
Asia Pacific Cancer Immunotherapy Market Trends:
Asia Pacific Cancer Immunotherapy Market Research Report:
An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
Regional and global diversity is analyzed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
Identifying DROC in the current market and their impact in altering the market dynamics.
Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial analysis with major competitors.
Expertise investment opportunities by an analyst to the individual and organization to have a better foothold in the market.
Along with these companies, there were many other companies considered/cited in the report while analyzing the Asia Pacific Cancer Immunotherapy market These companies hold substantial share-owning to the nature of the industry whereas rest of the market shares are marginal chunks to regional and local level manufacturers. Other players have considerable presence owing to its robust brand image, geographical reach and strong customer base
Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2Porter’s Five Force Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.4 SWOT Analysis
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1.1 Growth in adoption of immunotherapy over other treatment options
4.1.2 Increased development of bioinformatic tools enhancing drug development process
4.2.1 Cost issues
4.3.1 Rising number of clinical trials against many types of cancers in immunotherapy
4.3.2 Increased growth prospects in developing countries
4.4.1 Limited funds for the initiation of clinical trials
4.4.2 Complexity of cancers
Chapter 5 Asia Pacific Cancer Immunotherapy Market – By Production
5.1 Checkpoint Inhibitors
5.2 Monoclonal Antibodies
5.3 Cell Therapies
Chapter 6 Asia Pacific Cancer Immunotherapy Market – By Application
6.1 Colorectal Cancer
6.3 Prostate Cancer
6.4 Lung Cancer
6.5 Head & Neck Cancer
6.6 Multiple Myeloma
6.7 Breast Cancer
Chapter 7 Asia Pacific Cancer Immunotherapy Market – By End-user
Chapter 8 Asia Pacific Cancer Immunotherapy Market – By Geography
8.2.2 South Korea
Chapter 9 Asia Pacific Cancer Immunotherapy Market – Company Profiles
9.1 AstraZeneca Plc
9.2 ELI Lilly and Company
9.3 Bristol-Myers Squibb
9.4 Bayer AG
9.5. Novartis International AG
9.6 F. Hoffmann-La Roche Ltd
9.7 Janssen Global Services, LLC (Johnson and Johnson)
9.8 Pfizer Inc
9.9 Merck & Company, Inc.
9.10 Amgen Inc.
Chapter 10 Asia Pacific Cancer Immunotherapy Market – Competitive Landscape
10.1. Market Share Analysis
10.2. Strategies Adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
Chapter 11 Market Insights
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
Chapter 12 Appendix
12.1 List of Tables
12.2 List of Figures